메뉴 건너뛰기




Volumn 74, Issue SUPPL.110, 2008, Pages

Clinical Practice Guidelines for evidence-based use of erythropoietic- stimulating agents

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; BIOLOGICAL MARKER;

EID: 53449084681     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.270     Document Type: Article
Times cited : (21)

References (38)
  • 1
    • 33646345152 scopus 로고    scopus 로고
    • KDOQI: Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease
    • National Kidney Foundation
    • National Kidney Foundation. KDOQI: clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47(Suppl 3): S1-S146.
    • (2006) Am J Kidney Dis , vol.47 , Issue.SUPPL. 3
  • 2
    • 0038806683 scopus 로고    scopus 로고
    • The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients
    • Tonelli M, Winkelmayer WC, Jindal KK et al. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 2003; 64: 295-304.
    • (2003) Kidney Int , vol.64 , pp. 295-304
    • Tonelli, M.1    Winkelmayer, W.C.2    Jindal, K.K.3
  • 3
    • 0028117942 scopus 로고
    • Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients
    • Roth D, Smith RD, Schulman G et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994; 24: 777-784.
    • (1994) Am J Kidney Dis , vol.24 , pp. 777-784
    • Roth, D.1    Smith, R.D.2    Schulman, G.3
  • 4
    • 0028945387 scopus 로고
    • Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients
    • Revicki DA, Brown RE, Feeny DH et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995; 25: 548-554.
    • (1995) Am J Kidney Dis , vol.25 , pp. 548-554
    • Revicki, D.A.1    Brown, R.E.2    Feeny, D.H.3
  • 5
    • 0025373361 scopus 로고
    • Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis
    • Canadian Erythropoietin Study Group
    • Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1990; 300: 573-578.
    • (1990) BMJ , vol.300 , pp. 573-578
  • 6
    • 27144498003 scopus 로고    scopus 로고
    • Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease
    • Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-2189.
    • (2005) J Am Soc Nephrol , vol.16 , pp. 2180-2189
    • Parfrey, P.S.1    Foley, R.N.2    Wittreich, B.H.3
  • 7
    • 0033857652 scopus 로고    scopus 로고
    • Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy
    • Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335.
    • (2000) Kidney Int , vol.58 , pp. 1325-1335
    • Foley, R.N.1    Parfrey, P.S.2    Morgan, J.3
  • 8
    • 9144239992 scopus 로고    scopus 로고
    • Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial
    • Roger SD, McMahon LP, Clarkson A et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004; 15: 148-156.
    • (2004) J Am Soc Nephrol , vol.15 , pp. 148-156
    • Roger, S.D.1    McMahon, L.P.2    Clarkson, A.3
  • 9
    • 27144539133 scopus 로고    scopus 로고
    • Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD
    • Levin A, Djurdjev O, Thompson C et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005; 46: 799-811.
    • (2005) Am J Kidney Dis , vol.46 , pp. 799-811
    • Levin, A.1    Djurdjev, O.2    Thompson, C.3
  • 10
    • 33846642617 scopus 로고    scopus 로고
    • Target level for hemoglobin correction in patients with diabetes and CKD: Primary results of the Anemia Correction in Diabetes (ACORD) Study
    • Ritz E, Laville M, Bilous RW et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 2007; 49: 194-207.
    • (2007) Am J Kidney Dis , vol.49 , pp. 194-207
    • Ritz, E.1    Laville, M.2    Bilous, R.W.3
  • 11
    • 33751002326 scopus 로고    scopus 로고
    • Normalization of hemoglobin level in patients with chronic kidney disease and anemia
    • Drueke T, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
    • (2006) N Engl J Med , vol.355 , pp. 2071-2084
    • Drueke, T.1    Locatelli, F.2    Clyne, N.3
  • 12
    • 33750983605 scopus 로고    scopus 로고
    • Correction of anemia with epoetin alpha in chronic kidney disease
    • Singh A, Szczech L, Tang KL et al. Correction of anemia with epoetin alpha in chronic kidney disease. N Engl J Med 2006; 355: 2085-2096.
    • (2006) N Engl J Med , vol.355 , pp. 2085-2096
    • Singh, A.1    Szczech, L.2    Tang, K.L.3
  • 13
    • 0032572913 scopus 로고    scopus 로고
    • The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
    • Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
    • (1998) N Engl J Med , vol.339 , pp. 584-590
    • Besarab, A.1    Bolton, W.K.2    Browne, J.K.3
  • 14
    • 0037317068 scopus 로고    scopus 로고
    • A randomized controlled trial of hemoglobin normalization with epoetin alfa in predialysis and dialysis patients
    • Furuland H, Linde T, Ahlmen J et al. A randomized controlled trial of hemoglobin normalization with epoetin alfa in predialysis and dialysis patients. Nephrol Dial Transplant 2003; 18: 353-361.
    • (2003) Nephrol Dial Transplant , vol.18 , pp. 353-361
    • Furuland, H.1    Linde, T.2    Ahlmen, J.3
  • 15
    • 48649110499 scopus 로고    scopus 로고
    • Food and Drug Administration. FDA Advisory Committee Briefing Document Joint meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Committee: reassessment of the Risks of Erythropoiesis-Stimulating Agents (ESAs) administered for the treatment of anemia associated with chronic renal failure. In: Food and Drug Administration, Division of Medical Imaging and Hematology Products and Office of Surveillance and Epidemiology (OSE) (ed.), FDA: Rockville, MD, 2007.
    • Food and Drug Administration. FDA Advisory Committee Briefing Document Joint meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Committee: reassessment of the Risks of Erythropoiesis-Stimulating Agents (ESAs) administered for the treatment of anemia associated with chronic renal failure. In: Food and Drug Administration, Division of Medical Imaging and Hematology Products and Office of Surveillance and Epidemiology (OSE) (ed.), FDA: Rockville, MD, 2007.
  • 16
    • 33846669860 scopus 로고    scopus 로고
    • Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis
    • Phrommintikul A, Haas SJ, Elsik M et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369: 381-388.
    • (2007) Lancet , vol.369 , pp. 381-388
    • Phrommintikul, A.1    Haas, S.J.2    Elsik, M.3
  • 17
    • 0029151422 scopus 로고
    • Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients
    • Albitar S, Meulders Q, Hammoud H et al. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplant 1995; 10(Suppl 6): 40-43.
    • (1995) Nephrol Dial Transplant , vol.10 , Issue.SUPPL. 6 , pp. 40-43
    • Albitar, S.1    Meulders, Q.2    Hammoud, H.3
  • 18
    • 0036724273 scopus 로고    scopus 로고
    • Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients
    • Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 439-446.
    • (2002) Am J Kidney Dis , vol.40 , pp. 439-446
    • Besarab, A.1    Reyes, C.M.2    Hornberger, J.3
  • 19
    • 0030001078 scopus 로고    scopus 로고
    • Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin
    • Jensen JD, Madsen JK, Jensen LW. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin. Eur J Clin Pharmacol 1996; 50: 171-177.
    • (1996) Eur J Clin Pharmacol , vol.50 , pp. 171-177
    • Jensen, J.D.1    Madsen, J.K.2    Jensen, L.W.3
  • 20
    • 0032572918 scopus 로고    scopus 로고
    • Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients
    • Kaufman JS, Reda DJ, Fye CL et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998; 339: 578-583.
    • (1998) N Engl J Med , vol.339 , pp. 578-583
    • Kaufman, J.S.1    Reda, D.J.2    Fye, C.L.3
  • 21
    • 0031067025 scopus 로고    scopus 로고
    • Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients
    • Parker KP, Mitch WE, Stivelman JC et al. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients. J Am Soc Nephrol 1997; 8: 288-293.
    • (1997) J Am Soc Nephrol , vol.8 , pp. 288-293
    • Parker, K.P.1    Mitch, W.E.2    Stivelman, J.C.3
  • 22
    • 0026543474 scopus 로고
    • Cost benefits of low dose subcutaneous erythropoietin in patients with anemia of end stage renal disease
    • Stevens ME, Summerfield GP, Hall AA et al. Cost benefits of low dose subcutaneous erythropoietin in patients with anemia of end stage renal disease. BMJ 1992; 304: 474-477.
    • (1992) BMJ , vol.304 , pp. 474-477
    • Stevens, M.E.1    Summerfield, G.P.2    Hall, A.A.3
  • 23
    • 0026565505 scopus 로고
    • Crossover comparison of intravenous and subcutaneous erythropoietin in hemodialysis patients
    • Tomson CR, Feehally J, Walls J. Crossover comparison of intravenous and subcutaneous erythropoietin in hemodialysis patients. Nephrol Dial Transplant 1992; 7: 129-132.
    • (1992) Nephrol Dial Transplant , vol.7 , pp. 129-132
    • Tomson, C.R.1    Feehally, J.2    Walls, J.3
  • 24
    • 23044449036 scopus 로고    scopus 로고
    • Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population
    • Vercaigne LM, Collins DM, Penner SB. Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population. J Clin Pharmacol 2005; 45: 895-900.
    • (2005) J Clin Pharmacol , vol.45 , pp. 895-900
    • Vercaigne, L.M.1    Collins, D.M.2    Penner, S.B.3
  • 25
    • 33144454609 scopus 로고    scopus 로고
    • Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis
    • Moist LM, Muirhead N, Wazny LD et al. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis. Ann Pharmacother 2006; 40: 198-203.
    • (2006) Ann Pharmacother , vol.40 , pp. 198-203
    • Moist, L.M.1    Muirhead, N.2    Wazny, L.D.3
  • 26
    • 20844450196 scopus 로고    scopus 로고
    • Epoetin-induced autoimmune pure red cell aplasia
    • Casadevall N, Eckardt KU, Rossert J. Epoetin-induced autoimmune pure red cell aplasia. J Am Soc Nephrol 2005; 16(Suppl 1): S67-S69.
    • (2005) J Am Soc Nephrol , vol.16 , Issue.SUPPL. 1
    • Casadevall, N.1    Eckardt, K.U.2    Rossert, J.3
  • 27
    • 19044392727 scopus 로고    scopus 로고
    • The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes
    • Boven K, Stryker S, Knight J et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005; 67: 2346-2353.
    • (2005) Kidney Int , vol.67 , pp. 2346-2353
    • Boven, K.1    Stryker, S.2    Knight, J.3
  • 28
    • 33646181084 scopus 로고    scopus 로고
    • Clinical implications of converting stable hemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa
    • Aarup M, Bryndum J, Dieperink H et al. Clinical implications of converting stable hemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrol Dial Transplant 2006; 21: 1312-1316.
    • (2006) Nephrol Dial Transplant , vol.21 , pp. 1312-1316
    • Aarup, M.1    Bryndum, J.2    Dieperink, H.3
  • 29
    • 0037317083 scopus 로고    scopus 로고
    • Treatment of anemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo)
    • Locatelli F, Canaud B, Giacardy F et al. Treatment of anemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003; 18: 362-369.
    • (2003) Nephrol Dial Transplant , vol.18 , pp. 362-369
    • Locatelli, F.1    Canaud, B.2    Giacardy, F.3
  • 30
    • 33845584069 scopus 로고    scopus 로고
    • Hospital-acquired infections related to contaminated substances
    • Vonberg RP, Gastmeier P. Hospital-acquired infections related to contaminated substances. J Hosp Infect 2007; 65: 15-23.
    • (2007) J Hosp Infect , vol.65 , pp. 15-23
    • Vonberg, R.P.1    Gastmeier, P.2
  • 31
    • 3242780941 scopus 로고    scopus 로고
    • Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial
    • Gouva C, Nikolopoulos P, Ioannidis JP et al. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66: 753-760.
    • (2004) Kidney Int , vol.66 , pp. 753-760
    • Gouva, C.1    Nikolopoulos, P.2    Ioannidis, J.P.3
  • 32
    • 14044259130 scopus 로고    scopus 로고
    • Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: Recommendations for minimization of risk
    • Cournoyer D, Toffelmire EB, Wells GA et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol 2004; 15: 2728-2734.
    • (2004) J Am Soc Nephrol , vol.15 , pp. 2728-2734
    • Cournoyer, D.1    Toffelmire, E.B.2    Wells, G.A.3
  • 33
    • 23144460027 scopus 로고    scopus 로고
    • Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study
    • Provenzano R, Bhaduri S, Singh AK. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol 2005; 64: 113-123.
    • (2005) Clin Nephrol , vol.64 , pp. 113-123
    • Provenzano, R.1    Bhaduri, S.2    Singh, A.K.3
  • 34
    • 27744500483 scopus 로고    scopus 로고
    • Long-term outcome of individuals with pure red cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant epoetin: A follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project
    • Bennett CL, Cournoyer D, Carson KR et al. Long-term outcome of individuals with pure red cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 2005; 106: 3343-3347.
    • (2005) Blood , vol.106 , pp. 3343-3347
    • Bennett, C.L.1    Cournoyer, D.2    Carson, K.R.3
  • 35
    • 0141678217 scopus 로고    scopus 로고
    • Protocolized anemia management with erythropoietin in hemodialysis patients: A randomized controlled trial
    • Brimble KS, Rabbat CG, McKenna P et al. Protocolized anemia management with erythropoietin in hemodialysis patients: a randomized controlled trial. J Am Soc Nephrol 2003; 14: 2654-2661.
    • (2003) J Am Soc Nephrol , vol.14 , pp. 2654-2661
    • Brimble, K.S.1    Rabbat, C.G.2    McKenna, P.3
  • 36
    • 0031782623 scopus 로고    scopus 로고
    • Prospective evaluation of an anemia treatment algorithm in hemodialysis patients
    • Patterson P, Allon M. Prospective evaluation of an anemia treatment algorithm in hemodialysis patients. Am J Kidney Dis 1998; 32: 635-641.
    • (1998) Am J Kidney Dis , vol.32 , pp. 635-641
    • Patterson, P.1    Allon, M.2
  • 37
    • 0035499472 scopus 로고    scopus 로고
    • Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit
    • To LL, Stoner CP, Stolley SN et al. Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit. Am J Health Syst Pharm 2001; 58: 2061-2065.
    • (2001) Am J Health Syst Pharm , vol.58 , pp. 2061-2065
    • To, L.L.1    Stoner, C.P.2    Stolley, S.N.3
  • 38
    • 48649091961 scopus 로고    scopus 로고
    • The impact of a nursing led anemia protocol on hemoglobin and erythropoietin requirements
    • abstract
    • Culleton B, Hemmelgarn B, Hons RB. The impact of a nursing led anemia protocol on hemoglobin and erythropoietin requirements. Am Soc of Nephrol Confer 2003 (abstract).
    • (2003) Am Soc of Nephrol Confer
    • Culleton, B.1    Hemmelgarn, B.2    Hons, R.B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.